Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This research study will determine the proportion of patients with lowest minimal residual
disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal
residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in
the bone marrow.
For patients who become MRD "negative" (i.e. less than 1 cancer cell out of 100,000) at the
end of 6 cycles of therapy, this study will study if that good response can be maintained
with 3 additional cycles of treatment instead of use of autologous hematopoietic cell
transplantation (AHCT).
For patients who are MRD "positive" at the end of 6 cycles of therapy, this study will answer
whether more patients can become and remain MRD "negative" with AHCT plus teclistamab in
combination with daratumumab when compared with patients who undergo AHCT followed by
lenalidomide (an established anti-myeloma drug) plus daratumumab.